Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REPLIGEN CORP Director's Dealing 2021

Sep 2, 2021

30826_dirs_2021-09-02_1a999c5a-a4e7-4305-9bbc-712355cf0b92.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2021-08-30

Reporting Person: KURIYEL RALF (Senior VP, R&D)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-08-30 Common Stock S 4001 $282.13 Disposed 17354 Direct

Footnotes

F1: $282.13 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.10 to $282.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.